L R Bailey

Suggest Changes
Learn More
7013 Background: In two Phase III trials (INTACT 1 & 2), gefitinib ('Iressa', ZD1839) in combination with first-line platinum-based chemotherapy regimens failed to show benefit in terms of survival(More)
7024 Background: Two double-blind placebo-controlled randomized multicenter trials (INTACT 1 & 2) in NSCLC failed to show survival benefit for gefitinib ('Iressa', ZD1839) in combination with(More)
  • 1